Bristol Myers Drug Delays Tumor Growth

Bristol Myers Squibb announced on Monday that its experimental cancer therapy, RYZ101, has demonstrated a significant delay in disease progression among patients with rare, advanced gastrointestinal and pancreatic tumors. These patients had previously undergone earlier treatments without success.

RYZ101, acquired through Bristol Myers' $4.1 billion takeover of RayzeBio, is a radiopharmaceutical therapy that utilizes the radioactive isotope actinium-225. This class of drugs functions by delivering radioactive particles directly to tumorous tissue, aiming to kill cancer cells. The therapy was tested in a late-stage trial for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that had progressed after Lutetium-177-based therapy.

The company stated that the drug's safety profile is consistent with prior studies and intends to present detailed data to regulatory bodies. While RYZ101 shows promise, some analysts suggest that newer alpha-emitting therapies might limit its future market potential. The therapy is also under investigation for metastatic breast cancer.